Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Ayyoub

Showing results (31-40 of 88) with videos related to

Pageof 9
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cellsLucie Leveque, Florence Deknuydt, Gilles Bioley, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 2005
A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patientsMaha Ayyoub, Naira E Souleimanian, Emmanuelle Godefroy, et al.
Clinical Immunology (Orlando, Fla.)|July 4, 2006
Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II allelesEmmanuelle Godefroy, Luigi Scotto, Naira E Souleimanian, et al.
Clinical Immunology (Orlando, Fla.)|January 2, 2008
Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ TregsValeria Tosello, Kunle Odunsi, Naira E Souleimanian, et al.
Cancer Immunology, Immunotherapy : CII|December 23, 2006
Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individualsEmmanuelle Godefroy, Yu Wang, Naira E Souleimanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2009
Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoireGilles Bioley, Christelle Dousset, Alice Yeh, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1Frédérique-Anne Le Gal, Maha Ayyoub, Valérie Dutoit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccineGilles Bioley, Philippe Guillaume, Immanuel Luescher, et al.
Cancer Research|May 19, 2006
Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responsesLaurence Chapatte, Maha Ayyoub, Sandra Morel, et al.
Cancer Research|January 19, 2012
Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivoAhmed Hamaï, Pascale Pignon, Isabelle Raimbaud, et al.
Pageof 9

Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cellsLucie Leveque, Florence Deknuydt, Gilles Bioley, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 2005
A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patientsMaha Ayyoub, Naira E Souleimanian, Emmanuelle Godefroy, et al.
Clinical Immunology (Orlando, Fla.)|July 4, 2006
Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II allelesEmmanuelle Godefroy, Luigi Scotto, Naira E Souleimanian, et al.
Clinical Immunology (Orlando, Fla.)|January 2, 2008
Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ TregsValeria Tosello, Kunle Odunsi, Naira E Souleimanian, et al.
Cancer Immunology, Immunotherapy : CII|December 23, 2006
Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individualsEmmanuelle Godefroy, Yu Wang, Naira E Souleimanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2009
Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoireGilles Bioley, Christelle Dousset, Alice Yeh, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1Frédérique-Anne Le Gal, Maha Ayyoub, Valérie Dutoit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccineGilles Bioley, Philippe Guillaume, Immanuel Luescher, et al.
Cancer Research|May 19, 2006
Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responsesLaurence Chapatte, Maha Ayyoub, Sandra Morel, et al.
Cancer Research|January 19, 2012
Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivoAhmed Hamaï, Pascale Pignon, Isabelle Raimbaud, et al.
Pageof 9